Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

CYLD activates epithelial to mesenchymal transition. 3 / 3

| 1 2

➶

reach

"The Tumor Suppressor CYLD Inhibits Mammary Epithelial to Mesenchymal Transition by the Coordinated Inhibition of YAP and TAZ and TGF Signaling."

32722292

➶

eidos

"We found that downregulation of either YAP or TAZ prevented the EMT that is induced by CYLD downregulation ( Figure 5d ) ."

32722292

➶

reach

"CYLD downregulation or inactivation induced an epithelial to mesenchymal transition of mammary epithelial cells that was dependent on the concomitant activation of the transcription factors Yes associated protein (YAP)/transcriptional coactivator with PDZ binding motif (TAZ) and transforming growth factor beta (TGF) signaling."

32722292

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...

Other Services

This Service

This Project

IndraLab

Statements

CYLD activates epithelial to mesenchymal transition. 3 / 3

Our Sources:

Databases

Reading